National Prescription Opiate Litigation
Prescription opioids exert their effects primarily through activation of mu-opioid receptors, leading to analgesia, euphoria, and reinforcement. Neurobiological effects include increased dopamine release in reward pathways, neuroadaptations such as receptor downregulation, tolerance, and structural brain changes associated with dependence. Overdose causes respiratory depression, which can be fatal. Dependence develops through tolerance, withdrawal, and compulsive use driven by neuroplastic changes. Injuries include overdose, respiratory depression, neonatal abstinence syndrome, cognitive impairments, and long-term health consequences.
2,927
Pending actions
3,182
Total actions filed
Active
Status
12/05/2017
Established
Filing deadline
The court documents indicate that filing deadlines are generally within four years of injury or discovery of injury, with specific court-ordered deadlines for pleadings and amendments. Deadlines around the end of 2026 are emphasized, with some extensions granted.
Who qualifies
Plaintiffs must demonstrate exposure to prescription opioids during specific periods, notably around 2012-2013, with usage over a certain duration and possibly exceeding certain dosage thresholds. They must establish a causal link between their opioid prescriptions and harm, such as addiction or overdose. The criteria often include residency in certain jurisdictions during the relevant period. Filing deadlines are generally within four years of injury or discovery, with specific court-ordered deadlines for pleadings and amendments.
Products involved
- OxyContin
- Percocet
- Fentanyl (Duragesic, Sublimaze)
- Morphine (MS Contin, Kadian)
- Oxymorphone (Opana)
- Hydromorphone (Dilaudid)
- Methadone
- Codeine
Alleged injuries
- Opioid Use Disorder (OUD)
- Overdose and Poisoning
- Neonatal Abstinence Syndrome (NAS)
- Chronic Pain Conditions
- Respiratory Depression
- Liver and Kidney Damage
- Infectious Diseases (HIV, hepatitis C)
- Psychiatric Disorders (depression, anxiety)
- Physical Injuries (falls, trauma)
- Other Substance Use Disorders
Bellwether trials
The upcoming bellwether trials are scheduled to commence in 2026, with some sources indicating that the first trials could be later in the year. Recent major settlements include a $7.4 billion settlement with Purdue Pharma and a $26 billion nationwide settlement, both approved in early 2026. The case count has stabilized with most claims resolved or settled, and ongoing settlement negotiations continue, reflecting a maturing litigation landscape.
Settlement landscape
Total settlement amounts exceeding $50 billion have been announced, with major settlements including a $7.4 billion agreement with Purdue Pharma and a $26 billion nationwide settlement. These funds are allocated among states and localities, with some pending court approval. Individual case values vary significantly based on injury severity and other factors, but specific per-claim estimates are not publicly disclosed.
Lead counsel
- Greene Ketchum Farrell Bailey & Tweel, LLP
- Motley Rice LLC
- Leiff Cabraser Heimann & Bernstein LLP
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
